Relationship between the Presence of Human Papillomavirus in the Female Urethra and Recurrent Urinary Tract Infections
Abstract
1. Introduction
2. Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Lyu, Z.; Feng, X.; Li, N.; Zhao, W.; Wei, L.; Chen, Y.; Yang, W.; Ma, H.; Yao, B.; Zhang, K.; et al. Human papillomavirus in semen and the risk for male infertility: A systematic review and meta-analysis. BMC Infect. Dis. 2017, 17, 714. [Google Scholar] [CrossRef] [PubMed]
- EAU-Guidelines-on-Urological-Infections-2024. Available online: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Urological-Infections-2024.pdf (accessed on 11 June 2024).
- Rodríguez-Álvarez, M.I.; Gómez-Urquiza, J.L.; Husein-El Ahmed, H.; Albendín-García, L.; Gómez-Salgado, J.; Cañadas-De la Fuente, G.A. Prevalence and Risk Factors of Human Papillomavirus in Male Patients: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health 2018, 15, 2210. [Google Scholar] [CrossRef]
- Shigehara, K.; Sasagawa, T.; Namiki, M. Human papillomavirus infection and pathogenesis in urothelial cells: A mini-review. J. Infect. Chemother. 2014, 20, 741–747. [Google Scholar] [CrossRef] [PubMed]
- Wiener, J.S.; Walther, P.J. A high association of oncogenic human papillomaviruses with carcinomas of the female urethra: Polymerase chain reaction-based analysis of multiple histological types. J. Urol. 1994, 151, 49–53. [Google Scholar] [CrossRef]
- Aglianò, A.M.; Gazzaniga, P.; Cervigni, M.; Gradilone, A.; Napolitano, M.; Pastore, L.I.; Manzari, V.; Frati, L.; Vecchione, A. Detection of Human PapillomavirusType 16 DNA Sequences in Paraffin-Embedded Tissues from the Female Urinary Tract. Urol. Int. 2010, 52, 208–212. [Google Scholar] [CrossRef] [PubMed]
- Lorenzo-Gómez, M.F.; Foley, S.; Nickel, J.C.; García-Cenador, M.B.; Padilla-Fernández, B.Y.; González-Casado, I.; Martínez-Huélamo, M.; Yang, B.; Blick, C.; Ferreira, F.; et al. Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections. NEJM Evid. 2022, 1, EVIDoa2100018. [Google Scholar] [CrossRef]
- Wang, R.; Huang, H.; Yu, C.; Li, X.; Wang, Y.; Xie, L. Current status and future directions for the development of human papillomavirus vaccines. Front. Immunol. 2024, 15, 1362770. [Google Scholar] [CrossRef]
- Otero-Muriel, I.J.; Jiménez-Giraldo, S.; García-Perdomo, H.A. The association between the human papillomavirus (HPV) and the diagnosis of bladder cancer: Systematic review and meta-analysis. Actas Urol. Esp. 2024, 48, 427–436. [Google Scholar] [CrossRef]
- Ibishev, K.S.; Mamedov, V.K.; Migacheva, N.B.; Kogan, M.I. Immunological parameters of urine in differential diagnosis of chronic recurrent cystitis in women. Urologiia 2024, 1, 10–16. [Google Scholar] [CrossRef]
- Bhide, A.; Tailor, V.; Khullar, V. Interstitial cystitis/bladder pain syndrome and recurrent urinary tract infection and the potential role of the urinary microbiome. Post Reprod. Health 2020, 26, 87–90. [Google Scholar] [CrossRef]
- Chen, Y.Y.; Su, T.H.; Lau, H.H. Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: A meta-analysis of randomized controlled trials. Int. Urogynecol. J. 2021, 32, 17–25. [Google Scholar] [CrossRef] [PubMed]
- Visalli, G.; Facciolà, A.; D’Aleo, F.; Pinzone, M.R.; Condorelli, F.; Picerno, I.; Nunnari, G.; Pellicanò, G.F.; Ceccarelli, M.; Venanzi Rullo, E. HPV and urinary bladder carcinoma: A review of the literature. World Cancer Res. J. 2018, 5, 1038–1049. [Google Scholar]
- Flores-Mireles, A.L.; Walker, J.N.; Caparon, M.; Hultgren, S.J. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 2015, 13, 269–284. [Google Scholar] [CrossRef]
- Price, J.R.; Guran, L.A.; Gregory, W.T.; McDonagh, M.S. Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: A systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2016, 215, 548–560. [Google Scholar] [CrossRef]
- Ahmed, H.; Davies, F.; Francis, N.; Farewell, D.; Butler, C.; Paranjothy, S. Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: Systematic review and meta-analysis of randomised trials. BMJ Open 2017, 7, e015233. [Google Scholar] [CrossRef]
- Nalliah, S.; Fong, J.S.H.; Thor, A.Y.Y.; Lim, O.H. The use of chemotherapeutic agents as prophylaxis for recurrent urinary tract infection in healthy nonpregnant women: A network meta-analysis. Indian. J. Urol. 2019, 35, 147–155. [Google Scholar] [CrossRef] [PubMed]
- Arnold, J.J.; Hehn, L.E.; Klein, D.A. Common Questions About Recurrent Urinary Tract Infections in Women. Am. Fam. Physician 2016, 93, 560–569. [Google Scholar]
- Lorenzo-Gómez, M.F.; Padilla-Fernández, B.; García-Cenador, M.B.; Virseda-Rodríguez, Á.J.; Martín-García, I.; Sánchez-Escudero, A.; Vicente-Arroyo, M.J.; Mirón-Canelo, J.A. Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections. Front. Cell Infect. Microbiol. 2015, 5, 50. [Google Scholar]
- Martin-Cruz, L.; Sevilla-Ortega, C.; Benito-Villalvilla, C.; Diez-Rivero, C.M.; Sanchez-Ramón, S.; Subiza, J.L.; Palomares, O. A Combination of Polybacterial MV140 and Candida albicans V132 as a Potential Novel Trained Immunity-Based Vaccine for Genitourinary Tract Infections. Front. Immunol. 2021, 11, 612269. [Google Scholar] [CrossRef]
- Benito-Villalvilla, C.; Cirauqui, C.; Diez-Rivero, C.M.; Casanovas, M.; Subiza, J.L.; Palomares, O. MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88. Mucosal Immunol. 2017, 10, 924–935. [Google Scholar] [CrossRef]
- Wheeler, C.M.; Hunt, W.C.; Cuzick, J.; Langsfeld, E.; Pearse, A.; Montoya, G.D.; Robertson, M.; Shearman, C.A.; Castle, P.E. A population-based study of human papillomavirus genotype prevalence in the United States: Baseline measures prior to mass human papillomavirus vaccination. Int. J. Cancer 2013, 132, 198–207. [Google Scholar] [CrossRef] [PubMed]
- Gakis, G.; Witjes, J.A.; Compérat, E.; Cowan, N.C.; De Santis, M.; Lebret, T.; Ribal, M.J.; Sherif, A.M. EAU Guidelines on Primary Urethral Carcinoma. Eur. Urol. 2013, 64, 823–830. [Google Scholar] [CrossRef] [PubMed]
NHPV n = 72 | HPV n = 66 | p-Value (t-Student) | |||
---|---|---|---|---|---|
Age (years), average ± SD | 48.75 ± 17.57 | 39.09 ± 12.8 | 0.001 | ||
BMI (kg/m2), average ± SD | 22.54 ± 1.25 | 22.76 ± 1.58 | 0.189 | ||
Follow-up time (in days), average ± SD | 1975.35 ± 1160 | 2634 ± 1609 | 0.0017 | ||
Consultation symptoms | N | % | N | % | p-value (Chi-square) |
| 48 | 66.67 | 36 | 54.55 | 0.1649 |
| 30 | 41.67 | 24 | 36.36 | 0.6014 |
| 18 | 25.00 | 18 | 27.27 | 0.8468 |
| 30 | 41.67 | 24 | 36.36 | 0.6014 |
| 6 | 8.33 | 42 | 63.64 | 0.0001 |
Groups | NHPV n = 72 | HPV n = 66 | Total | p-Value (Chi-Square) | |||
---|---|---|---|---|---|---|---|
Pathogens | n | % | n | % | n | % | |
Enterococcus faecalis | 6 | 8.33 | 24 | 36.36 | 30 | 21.74 | 0.0001 |
Escherichia coli | 12 | 16.67 | 54 | 81.82 | 66 | 47.83 | 0.0001 |
Klebsiella pneumoniae | 12 | 16.67 | 30 | 45.45 | 42 | 30.43 | 0.0004 |
Sensitivity of antibiotics | |||||||
Amoxicillin | 12 | 16.67 | 42 | 63.64 | 54 | 39.13 | 0.0001 |
Cefuroxime | 12 | 16.67 | 30 | 45.45 | 42 | 30.43 | 0.0004 |
Ciprofloxacin | 18 | 25.00 | 24 | 36.36 | 42 | 30.43 | 0.1948 |
Fosfomycin | 12 | 16.67 | 60 | 90.91 | 72 | 52.17 | 0.0001 |
Gentamycin | 12 | 16.67 | 18 | 27.27 | 30 | 21.74 | 0.1515 |
Nitrofurantoin | 18 | 25.00 | 60 | 90.91 | 78 | 56.52 | 0.0001 |
Trimethoprim | 18 | 25.00 | 54 | 81.82 | 72 | 52.17 | 0.0001 |
Antibiotic Resistance | |||||||
Amoxicillin | 6 | 8.33 | 24 | 36.36 | 30 | 21.74 | 0.0001 |
Amoxicillin–clavulanate | 6 | 8.33 | 24 | 36.36 | 30 | 21.74 | 0.0001 |
Quinolones | 12 | 16.67 | 6 | 9.09 | 18 | 13.04 | 0.2143 |
Group | HPV n = 66 | |
---|---|---|
Genotypes | n | % |
G6 | 6 | 9.09 |
G31 | 6 | 9.09 |
G35 | 18 | 27.27 |
G42 | 18 | 27.27 |
G51 | 12 | 18.18 |
G52 | 6 | 9.09 |
G53 | 12 | 18.18 |
G61 | 6 | 9.09 |
G66 | 18 | 27.27 |
G70 | 6 | 9.09 |
G82 | 6 | 9.09 |
G89 | 12 | 18.18 |
Cluster | 1-NHPV | 2-HPV | Importance in Cluster Multivariate Analysis |
---|---|---|---|
Size | 43.50% (n 60) | 56.50% (n 78) | |
Sensitivity Nitrofurantoin | Most frequent category No (90%) | Most frequent category Yes (93.30%) | 0.96 |
Sensitivity Phosphomycin | Most frequent category No (90%) | Most frequent category Yes (84.60%) | 0.79 |
Sensitivity Trimetropim/sulfametoxazole | Most frequent category No (90%) | Most frequent category Yes (84.60%) | 0.79 |
Sensitivity Amoxicillin | Most frequent category No (100%) | Most frequent category Yes (69.20%) | 0.71 |
Follow up days | Mean 1137.08 SD 1160.37 Range 28–3929 | Mean 2634.00 SD 1609.017 Range 485–5421 | 0.68 |
Escherichia coli | Most frequent category No (90%) | Most frequent category Yes (76.90%) | 0.64 |
Wart | Most frequent category No (100%) | Most frequent category Yes (61.50%) | 0.60 |
Sensitivity Cefuroxime | Most frequent category No (100%) | Most frequent category (%) | 0.50 |
Klebsiella pneumoniae | Most frequent category No (100%) | Most frequent category Yes (53.80%) | 0.50 |
Ultrasound as a complementary test | Most frequent category No (80%) | Most frequent category Yes (53.80%) | 0.19 |
BMI | Mean 22.54 SD 1.25 Range 20.82–24.38 | Mean 22.76 SD 1.58 Range 19.15–24.38 | 0.11 |
Age | Mean 48,75 SD 17,578 Range 22–73 | Mean 39,09 SD 12.80 Range 24–63 | 0.9 |
Positive urine culture | Most frequent category Yes (60%) | Most frequent category Yes (61.50%) | 0.1 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mena-Ruiz, C.; Szczesnieski, J.J.; Márquez-Sánchez, M.; Padilla-Fernández, B.-Y.; Flores-Fraile, J.; Lorenzo-Gómez, M.-F. Relationship between the Presence of Human Papillomavirus in the Female Urethra and Recurrent Urinary Tract Infections. J. Clin. Med. 2024, 13, 5329. https://doi.org/10.3390/jcm13175329
Mena-Ruiz C, Szczesnieski JJ, Márquez-Sánchez M, Padilla-Fernández B-Y, Flores-Fraile J, Lorenzo-Gómez M-F. Relationship between the Presence of Human Papillomavirus in the Female Urethra and Recurrent Urinary Tract Infections. Journal of Clinical Medicine. 2024; 13(17):5329. https://doi.org/10.3390/jcm13175329
Chicago/Turabian StyleMena-Ruiz, Cristina, Julius Jan Szczesnieski, Magaly Márquez-Sánchez, Bárbara-Yolanda Padilla-Fernández, Javier Flores-Fraile, and María-Fernanda Lorenzo-Gómez. 2024. "Relationship between the Presence of Human Papillomavirus in the Female Urethra and Recurrent Urinary Tract Infections" Journal of Clinical Medicine 13, no. 17: 5329. https://doi.org/10.3390/jcm13175329
APA StyleMena-Ruiz, C., Szczesnieski, J. J., Márquez-Sánchez, M., Padilla-Fernández, B.-Y., Flores-Fraile, J., & Lorenzo-Gómez, M.-F. (2024). Relationship between the Presence of Human Papillomavirus in the Female Urethra and Recurrent Urinary Tract Infections. Journal of Clinical Medicine, 13(17), 5329. https://doi.org/10.3390/jcm13175329